Anixa Biosciences, Inc.
US ˙ NasdaqCM ˙ US03528H1095

Introduction

This page provides a comprehensive analysis of the known insider trading history of Robert Andrew Berman. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Robert Andrew Berman has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:NVNO / enVVeno Medical Corporation Chief Executive Officer, Director 222,236
US:ITUS / ITUS Corp. President & CEO, Director 61,553
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Robert Andrew Berman. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ANIX / Anixa Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ANIX / Anixa Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-06-02 ITUS BERMAN ROBERT ANDREW 100 0.8500 100 0.8500 85 237
2017-06-02 ITUS BERMAN ROBERT ANDREW 9,900 0.8800 9,900 0.8800 8,712
2015-07-21 ITUS BERMAN ROBERT ANDREW 5,000 5.7700 5,000 5.7700 28,850
2015-07-10 ITUSD BERMAN ROBERT ANDREW 200 4.0000 200 4.0000 800
2015-07-07 ITUSD BERMAN ROBERT ANDREW 200 3.8000 200 3.8000 760
2015-07-01 ITUSD BERMAN ROBERT ANDREW 500 3.9500 500 3.9500 1,975
2015-06-30 ITUSD BERMAN ROBERT ANDREW 600 3.7500 600 3.7500 2,250
2015-06-29 ITUSD BERMAN ROBERT ANDREW 1,400 4.0700 1,400 4.0700 5,698
2015-06-26 ITUSD BERMAN ROBERT ANDREW 312 5.0000 12 125.0000 1,560
2015-06-22 ITUS BERMAN ROBERT ANDREW 60,000 0.1504 60,000 0.1504 9,024
2015-06-19 ITUS BERMAN ROBERT ANDREW 20,000 0.1400 20,000 0.1400 2,800
2015-06-18 ITUS BERMAN ROBERT ANDREW 50,000 0.1297 50,000 0.1297 6,485
2015-06-17 ITUS BERMAN ROBERT ANDREW 50,000 0.1349 50,000 0.1349 6,745
2015-06-15 ITUS BERMAN ROBERT ANDREW 30,000 0.1360 30,000 0.1360 4,080
2015-06-11 ITUS BERMAN ROBERT ANDREW 25,000 0.1423 25,000 0.1423 3,558
2015-06-10 ITUS BERMAN ROBERT ANDREW 10,000 0.1449 10,000 0.1449 1,449
2015-06-09 ITUS BERMAN ROBERT ANDREW 10,000 0.1399 10,000 0.1399 1,399
2015-06-04 ITUS BERMAN ROBERT ANDREW 20,000 0.1625 20,000 0.1625 3,250
2015-06-01 ITUS BERMAN ROBERT ANDREW 30,000 0.1423 30,000 0.1423 4,269
2015-03-23 ITUS BERMAN ROBERT ANDREW 50,000 0.1217 50,000 0.1217 6,085
2015-03-20 ITUS BERMAN ROBERT ANDREW 50,000 0.1004 50,000 0.1004 5,020
2014-01-29 COPY BERMAN ROBERT ANDREW 6,994 0.3790 280 9.4750 2,651
2014-01-29 COPY BERMAN ROBERT ANDREW 3,006 0.3800 120 9.5000 1,142
2014-01-29 COPY BERMAN ROBERT ANDREW 2,500 0.4000 100 10.0000 1,000
2014-01-28 COPY BERMAN ROBERT ANDREW 2,500 0.3380 100 8.4500 845
2014-01-28 COPY BERMAN ROBERT ANDREW 18,305 0.3400 732 8.5000 6,224
2014-01-27 COPY BERMAN ROBERT ANDREW 5,000 0.2950 200 7.3750 1,475
2014-01-27 COPY BERMAN ROBERT ANDREW 7,500 0.3000 300 7.5000 2,250
2014-01-27 COPY BERMAN ROBERT ANDREW 4,500 0.3050 180 7.6250 1,372
2014-01-27 COPY BERMAN ROBERT ANDREW 20,000 0.3090 800 7.7250 6,180
2014-01-27 COPY BERMAN ROBERT ANDREW 2,500 0.3100 100 7.7500 775
2014-01-24 COPY BERMAN ROBERT ANDREW 5,000 0.2950 200 7.3750 1,475
2014-01-24 COPY BERMAN ROBERT ANDREW 2,500 0.2995 100 7.4875 749
2014-01-24 COPY BERMAN ROBERT ANDREW 1,000 0.3000 40 7.5000 300
2014-01-22 COPY BERMAN ROBERT ANDREW 23,000 0.2200 920 5.5000 5,060
2014-01-22 COPY BERMAN ROBERT ANDREW 22,000 0.2300 880 5.7500 5,060
2014-01-21 COPY BERMAN ROBERT ANDREW 25,000 0.2097 1,000 5.2425 5,242
2013-01-25 COPY BERMAN ROBERT ANDREW

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIX / Anixa Biosciences, Inc. Insider Trades
Insider Sales ANIX / Anixa Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ANIX / Anixa Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ANIX / Anixa Biosciences, Inc. Insider Trades
Insider Purchases NVNO / enVVeno Medical Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ANIX / Anixa Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2024-12-19 NVNO BERMAN ROBERT ANDREW 12,000 2.5500 12,000 2.5500 30,600 210 5.2500 32,400 105.88
2022-06-27 NVNO BERMAN ROBERT ANDREW 2,500 3.8000 2,500 3.8000 9,500
2021-11-19 NVNO BERMAN ROBERT ANDREW 2,000 7.4300 2,000 7.4300 14,860
2021-11-16 NVNO BERMAN ROBERT ANDREW 2,000 7.8700 2,000 7.8700 15,740
2021-05-18 HJLI BERMAN ROBERT ANDREW 3,000 5.4700 3,000 5.4700 16,410
2019-03-12 HJLI BERMAN ROBERT ANDREW 21,740 1.1500 870 28.7500 25,001
2019-03-12 HJLI BERMAN ROBERT ANDREW 18,382 1.3600 735 34.0000 25,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NVNO / enVVeno Medical Corporation Insider Trades
Insider Sales NVNO / enVVeno Medical Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ANIX / Anixa Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NVNO / enVVeno Medical Corporation Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Robert Andrew Berman as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2024-12-19 2024-12-19 4 NVNO enVVeno Medical Corp
Common Stock 		P - Purchase 12,000 222,236 5.71 2.55 30,600 566,702
2022-06-28 2022-06-27 4 NVNO enVVeno Medical Corp
Common Stock 		P - Purchase 2,500 210,236 1.20 3.80 9,500 798,897
2021-12-02 2021-11-30 4 NVNO enVVeno Medical Corp
Stock Options 		A - Award 349,781 349,781
2021-12-02 2021-11-30 4 NVNO enVVeno Medical Corp
Common Stock 		A - Award 200,000 207,736 2,585.32
2021-11-19 2021-11-19 4 NVNO enVVeno Medical Corp
Common Stock 		P - Purchase 2,000 7,736 34.87 7.43 14,860 57,478
2021-11-18 2021-11-16 4 NVNO enVVeno Medical Corp
Common Stock 		P - Purchase 2,000 5,736 53.53 7.87 15,740 45,142
2021-05-19 2021-05-18 4 HJLI Hancock Jaffe Laboratories, Inc.
Common Stock, $0.00001 par value 		P - Purchase 3,000 3,736 407.61 5.47 16,410 20,436
2021-02-22 2021-02-18 4 HJLI Hancock Jaffe Laboratories, Inc.
Stock Option 		A - Award 838,000 838,000
2020-07-21 2020-07-18 4 HJLI Hancock Jaffe Laboratories, Inc.
Stock Option 		A - Award 1,080,207 1,080,207
2020-07-21 2020-07-18 4 HJLI Hancock Jaffe Laboratories, Inc.
Stock Option 		J - Other -1,080,207 0 -100.00
2020-07-21 2020-07-18 4 HJLI Hancock Jaffe Laboratories, Inc.
Stock Option 		A - Award 1,000,000 1,000,000
2019-04-17 2019-03-12 4/A HJLI Hancock Jaffe Laboratories, Inc.
Common Stock 		P - Purchase 18,382 18,382 1.36 25,000 25,000
2019-03-14 2019-03-12 4 HJLI Hancock Jaffe Laboratories, Inc.
Common Stock 		P - Purchase 21,740 21,740 1.15 25,001 25,001
2018-09-26 2018-09-24 4 HJLI Hancock Jaffe Laboratories, Inc.
Stock Option (Right to Buy) 		A - Award 1,080,207 1,080,207 2.71 2,927,361 2,927,361
2017-06-05 2017-06-02 4 ITUS ITUS Corp
Common Stock 		P - Purchase 9,900 61,553 19.17 0.88 8,712 54,167
2017-06-05 2017-06-02 4 ITUS ITUS Corp
Common Stock 		P - Purchase 100 51,653 0.19 0.85 85 43,905
2017-04-04 2017-04-03 4 ITUS ITUS Corp
Subscription Right 		X - Other -5,995 0 -100.00
2017-04-04 2017-04-03 4 ITUS ITUS Corp
Common Stock 		X - Other 5,995 51,553 13.16 2.38 14,268 122,696
2016-02-19 2016-02-18 4 ITUS ITUS Corp
Employee Stock Options (Right to Buy) 		A - Award 200,000 200,000
2015-07-24 2015-07-21 4 ITUS ITUS Corp
Common Stock 		P - Purchase 5,000 45,558 12.33 5.77 28,850 262,870
2015-07-14 2015-07-10 4 ITUSD ITUS Corp
Common Stock 		P - Purchase 200 40,558 0.50 4.00 800 162,232
2015-07-09 2015-07-07 4 ITUSD ITUS Corp
Common Stock 		P - Purchase 200 40,358 0.50 3.80 760 153,360
2015-07-02 2015-07-01 4 ITUSD ITUS Corp
Common Stock 		P - Purchase 500 40,158 1.26 3.95 1,975 158,624
2015-07-02 2015-06-30 4 ITUSD ITUS Corp
Common Stock 		P - Purchase 600 39,658 1.54 3.75 2,250 148,718
2015-07-01 2015-06-29 4 ITUSD ITUS Corp
Common Stock 		P - Purchase 1,400 39,058 3.72 4.07 5,698 158,966
2015-07-01 2015-06-26 4 ITUSD ITUS Corp
Common Stock 		P - Purchase 312 37,658 0.84 5.00 1,560 188,290
2015-06-23 2015-06-22 4 ITUS ITUS Corp
Common Stock 		P - Purchase 60,000 933,650 6.87 0.15 9,024 140,421
2015-06-23 2015-06-19 4 ITUS ITUS Corp
Common Stock 		P - Purchase 20,000 873,650 2.34 0.14 2,800 122,311
2015-06-18 2015-06-18 4 ITUS ITUS Corp
Common Stock 		P - Purchase 50,000 853,650 6.22 0.13 6,485 110,718
2015-06-18 2015-06-17 4 ITUS ITUS Corp
Common Stock 		P - Purchase 50,000 803,650 6.63 0.13 6,745 108,412
2015-06-18 2015-06-15 4 ITUS ITUS Corp
Common Stock 		P - Purchase 30,000 753,650 4.15 0.14 4,080 102,496
2015-06-11 2015-06-11 4 ITUS ITUS Corp
Common Stock 		P - Purchase 25,000 723,650 3.58 0.14 3,558 102,975
2015-06-10 2015-06-10 4 ITUS ITUS Corp
Common Stock 		P - Purchase 10,000 698,650 1.45 0.14 1,449 101,234
2015-06-10 2015-06-09 4 ITUS ITUS Corp
Common Stock 		P - Purchase 10,000 688,650 1.47 0.14 1,399 96,342
2015-06-04 2015-06-04 4 ITUS ITUS Corp
Common Stock 		P - Purchase 20,000 678,650 3.04 0.16 3,250 110,281
2015-06-01 2015-06-01 4 ITUS ITUS Corp
Common Stock 		P - Purchase 30,000 658,650 4.77 0.14 4,269 93,726
2015-03-24 2015-03-23 4 ITUS ITUS Corp
Common Stock 		P - Purchase 50,000 628,650 8.64 0.12 6,085 76,507
2015-03-24 2015-03-20 4 ITUS ITUS Corp
Common Stock 		P - Purchase 50,000 578,650 9.46 0.10 5,020 58,096
2015-02-05 2015-02-05 4 ITUS ITUS Corp
Employee Stock Option 		A - Award 1,000,000 1,000,000
2015-02-05 2015-02-05 4 ITUS ITUS Corp
Employee Stock Option 		D - Sale to Issuer -1,000,000 0 -100.00
2015-02-05 2015-02-05 4 ITUS ITUS Corp
Employee Stock Option 		A - Award 8,000,000 8,000,000
2015-02-05 2015-02-05 4 ITUS ITUS Corp
Employee Stock Option 		A - Award 8,000,000 8,000,000
2015-02-05 2015-02-05 4 ITUS ITUS Corp
Employee Stock Option 		D - Sale to Issuer -8,000,000 0 -100.00
2015-02-05 2015-02-05 4 ITUS ITUS Corp
Employee Stock Option 		D - Sale to Issuer -8,000,000 0 -100.00
2014-01-29 2014-01-29 4 COPY COPYTELE INC
Common Stock 		P - Purchase 2,500 190,707 1.33 0.40 1,000 76,283
2014-01-29 2014-01-29 4 COPY COPYTELE INC
Common Stock 		P - Purchase 3,006 165,707 1.85 0.38 1,142 62,969
2014-01-29 2014-01-29 4 COPY COPYTELE INC
Common Stock 		P - Purchase 6,994 162,701 4.49 0.38 2,651 61,664
2014-01-29 2014-01-28 4 COPY COPYTELE INC
Common Stock 		P - Purchase 18,305 155,707 13.32 0.34 6,224 52,940
2014-01-29 2014-01-28 4 COPY COPYTELE INC
Common Stock 		P - Purchase 2,500 137,402 1.85 0.34 845 46,442
2014-01-29 2014-01-27 4 COPY COPYTELE INC
Common Stock 		P - Purchase 2,500 134,902 1.89 0.31 775 41,820
2014-01-29 2014-01-27 4 COPY COPYTELE INC
Common Stock 		P - Purchase 20,000 132,402 17.79 0.31 6,180 40,912
2014-01-29 2014-01-27 4 COPY COPYTELE INC
Common Stock 		P - Purchase 4,500 112,402 4.17 0.30 1,372 34,283
2014-01-29 2014-01-27 4 COPY COPYTELE INC
Common Stock 		P - Purchase 7,500 107,902 7.47 0.30 2,250 32,371
2014-01-29 2014-01-27 4 COPY COPYTELE INC
Common Stock 		P - Purchase 5,000 100,402 5.24 0.30 1,475 29,619
2014-01-28 2014-01-24 4 COPY COPYTELE INC
Common Stock 		P - Purchase 1,000 95,402 1.06 0.30 300 28,621
2014-01-28 2014-01-24 4 COPY COPYTELE INC
Common Stock 		P - Purchase 2,500 94,402 2.72 0.30 749 28,273
2014-01-28 2014-01-24 4 COPY COPYTELE INC
Common Stock 		P - Purchase 5,000 91,902 5.75 0.30 1,475 27,111
2014-01-24 2014-01-22 4 COPY COPYTELE INC
Common Stock 		P - Purchase 22,000 86,902 33.90 0.23 5,060 19,987
2014-01-24 2014-01-22 4 COPY COPYTELE INC
Common Stock 		P - Purchase 23,000 64,902 54.89 0.22 5,060 14,278
2014-01-23 2014-01-21 4 COPY COPYTELE INC
Common Stock 		P - Purchase 25,000 41,902 147.91 0.21 5,242 8,787
2014-01-06 2014-01-02 4 COPY COPYTELE INC
Common Stock 		J - Other 5,236 16,902 44.88 0.19 1,000 3,228
2013-11-13 2013-11-08 4 COPY COPYTELE INC
Employee Stock Options (Right to Buy) 		A - Award 1,000,000 1,000,000
2013-07-16 2013-07-01 4 COPY COPYTELE INC
Common Stock 		J - Other 3,447 6,786 103.23 0.29 1,000 1,969
2013-01-29 2013-01-25 4 COPY COPYTELE INC
8% Convertible Debentures Due 2015 		P - Purchase 166,650
2013-01-29 2013-01-25 4 COPY COPYTELE INC
Common Stock Purchase Warrant 		P - Purchase 166,650 166,650
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)